Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2020’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)

– The report reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Post-Traumatic Stress Disorder (PTSD) therapeutics and enlists all their major and minor projects

– The report assesses Post-Traumatic Stress Disorder (PTSD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Actinogen Medical Ltd

Addex Therapeutics Ltd

Aision Biotechnologies Inc

Amorsa Therapeutics Inc

Anagin Inc

Aptinyx Inc

Armgo Pharma Inc

Artelo Biosciences Inc

Avicanna Inc

Azevan Pharmaceuticals Inc

Bionomics Ltd

Cannabis Science Inc

Catalyst Pharmaceuticals Inc

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Eli Lilly and Co

Embera NeuroTherapeutics Inc

EpiVario Inc

HolsboerMaschmeyer NeuroChemie GmbH

Immodulon Therapeutics Ltd

INVENT Pharmaceuticals Inc

Johnson & Johnson

Kdac Therapeutics Inc

Lixte Biotechnology Holdings Inc

NeuroNascent Inc

NeuroRx Inc

Neurovation Labs Inc

Omeros Corp

One World Cannabis Ltd

Otsuka Holdings Co Ltd

Quoin Pharmaceuticals Ltd

Sanofi

Scientus Pharma Inc

Seelos Therapeutics, Inc.

Tonix Pharmaceuticals Holding Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Post-Traumatic Stress Disorder (PTSD) Overview

Post-Traumatic Stress Disorder (PTSD) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Post-Traumatic Stress Disorder (PTSD) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Post-Traumatic Stress Disorder (PTSD) Companies Involved in Therapeutics Development

Actinogen Medical Ltd

Addex Therapeutics Ltd

Amorsa Therapeutics Inc

Anagin Inc

Aptinyx Inc

Artelo Biosciences Inc

Azevan Pharmaceuticals Inc

Bionomics Ltd

Cannabis Science Inc

Catalyst Pharmaceuticals Inc

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Eli Lilly and Co

Embera NeuroTherapeutics Inc

Immodulon Therapeutics Ltd

Johnson & Johnson

Lixte Biotechnology Holdings Inc

NeuroNascent Inc

Omeros Corp

Otsuka Holdings Co Ltd

Sanofi

Tonix Pharmaceuticals Holding Corp

Post-Traumatic Stress Disorder (PTSD) Drug Profiles

(metyrapone + oxazepam) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71743 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-3506 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-210 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brexpiprazole Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBISPTSD-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPP-115 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-107 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-87201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-107 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-40411813 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDAC-0001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketamine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

midomafetamine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

modafinil Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NNI-351 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-013 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRX-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRX-104 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYX-783 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QRX-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rycal Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-411298 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GPR83 for CNS and Immunological Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule To Inhibit ACSS2 for Post Traumatic Stress Disorder Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Central Nervous System Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor for Depression and Post-Traumatic Stress Disorder Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GRIA1 for Post-Traumatic Stress Disorder Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-246 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-1600 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-601 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UE-2343 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZL-006 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Post-Traumatic Stress Disorder (PTSD) Dormant Projects

Post-Traumatic Stress Disorder (PTSD) Discontinued Products

Post-Traumatic Stress Disorder (PTSD) Product Development Milestones

Featured News & Press Releases

Appendix

List of Tables

List of Tables

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Actinogen Medical Ltd, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Addex Therapeutics Ltd, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Aision Biotechnologies Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Amorsa Therapeutics Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Anagin Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Aptinyx Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Armgo Pharma Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Artelo Biosciences Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Avicanna Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Azevan Pharmaceuticals Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Bionomics Ltd, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Cannabis Science Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Catalyst Pharmaceuticals Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Chronos Therapeutics Ltd, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Corcept Therapeutics Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Eli Lilly and Co, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Embera NeuroTherapeutics Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by EpiVario Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Immodulon Therapeutics Ltd, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by INVENT Pharmaceuticals Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Johnson & Johnson, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Kdac Therapeutics Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Lixte Biotechnology Holdings Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by NeuroNascent Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by NeuroRx Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Neurovation Labs Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Omeros Corp, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by One World Cannabis Ltd, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Otsuka Holdings Co Ltd, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Quoin Pharmaceuticals Ltd, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Sanofi, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Scientus Pharma Inc, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Seelos Therapeutics, Inc., H1 2020

Post-Traumatic Stress Disorder (PTSD) – Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Dormant Projects, H1 2020

Post-Traumatic Stress Disorder (PTSD) – Dormant Projects, H1 2020 (Contd..1), H1 2020

Post-Traumatic Stress Disorder (PTSD) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports